RecruitingPhase 2NCT05621811

Different Doses of Naronapride Vs. Placebo in Gastroparesis

Studying Idiopathic gastroparesis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Dr. Falk Pharma GmbH
Intervention: Naronapride(drug)
Enrollment: 320 target
Eligibility: 18-75 years · All sexes
Timeline: 2023 – 2025

Study locations (20)

Dr Falk Investigational Site, Chula Vista, California, United States
Dr Falk Investigational Site, Lomita, California, United States
Dr Falk Investigational Site, Clearwater, Florida, United States
Dr Falk Investigational Site, Doral, Florida, United States
Dr Falk Investigational Site, Hollywood, Florida, United States
Dr Falk Investigational Site, Maitland, Florida, United States
Dr Falk Investigational Site, Miami, Florida, United States
Dr Falk Investigational Site, Viera, Florida, United States
Dr Falk Investigational Site, Topeka, Kansas, United States
Dr Falk Investigational Site, Crestview Hills, Kentucky, United States
Dr Falk Investigational Site, Houma, Louisiana, United States
Dr Falk Investigational Site, Marrero, Louisiana, United States
Dr Falk Investigational Site, Flint, Michigan, United States
Dr Falk Investigational Site, New York, New York, United States
Dr Falk Investigational Site, Tulsa, Oklahoma, United States
+5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05621811 on ClinicalTrials.gov

Other trials for Idiopathic gastroparesis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic gastroparesis →

← Back to all trials